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Redeﬁning the MED13L syndrome
Abidemi Adegbola1,2,3, Luciana Musante4, Bert Callewaert5, Patricia Maciel6,7, Hao Hu4, Bertrand Isidor8,9,
Sylvie Picker-Minh10,11, Cedric Le Caignec8,9, Barbara Delle Chiaie5, Olivier Vanakker5, Björn Menten5,
Annelies D’heedene5, Nele Bockaert12, Filip Roelens13, Karin Decaestecker14, João Silva15, Gabriela Soares16,
Fátima Lopes6,7, Hossein Najmabadi17, Kimia Kahrizi17, Gerald F Cox18, Steven P Angus19, John F Staropoli20,
Ute Fischer4, Vanessa Suckow4, Oliver Bartsch21, Andrew Chess1,2,3, Hans-Hilger Ropers4, Thomas F Wienker4,
Christoph Hübner10, Angela M Kaindl10,11 and Vera M Kalscheuer*,4
Congenital cardiac and neurodevelopmental deﬁcits have been recently linked to the mediator complex subunit 13-like
protein MED13L, a subunit of the CDK8-associated mediator complex that functions in transcriptional regulation through
DNA-binding transcription factors and RNA polymerase II. Heterozygous MED13L variants cause transposition of the great
arteries and intellectual disability (ID). Here, we report eight patients with predominantly novel MED13L variants who lack
such complex congenital heart malformations. Rather, they depict a syndromic form of ID characterized by facial
dysmorphism, ID, speech impairment, motor developmental delay with muscular hypotonia and behavioral difﬁculties.
We thereby deﬁne a novel syndrome and signiﬁcantly broaden the clinical spectrum associated with MED13L variants.
A prominent feature of the MED13L neurocognitive presentation is profound language impairment, often in combination with
articulatory deﬁcits.
European Journal of Human Genetics advance online publication, 11 March 2015; doi:10.1038/ejhg.2015.26
INTRODUCTION
Cardiovascular and central nervous system malformations are among
the most common birth defects.1 Although numerical chromosome
aberrations and microdeletion/duplication syndromes are a well-
known cause of congenital heart disease, few single genes have been
associated with isolated congenital heart disease.2 The mediator
complex subunit 13-like gene MED13L (MIM*608771; previously
known as THRAP2, PROSIT240, TRAP240L and KIAA1025) is one of
few genes linked to the pathogenesis of more severe cyanotic forms of
non-syndromic congenital heart disease including dextro-looped
transposition of the great arteries (d-TGA; MIM #608808)3 and other
complex congenital cardiac defects.3,4
MED13L encodes a subunit of the mediator complex that
functions as a transcriptional coactivator for nearly all RNA
polymerase II-dependent genes.5–8 MED13 (and likely MED13L)
links mediator complex activity regulating cyclin-dependent kinase
8 (CDK8) module to core mediator and thus also regulates the
complex activity.9
The involvement of MED13L in congenital heart defects,
in particular in isolated d-TGA, was ﬁrst shown in a study
reporting an interruption of this gene as well as three missense
variants in four patients.3 At the same time, Musante et al10 reported a
Noonan-like phenotype in a boy with a paternally inherited balanced
translocation with one of the breakpoints mapping 28- kb upstream of
MED13L exon 1. Heterozygous variants in MED13L have been
described in a small number of patients presenting with dysmorphic
features, developmental delay and complex cardiac defects.4 On the
basis of these ﬁndings, MED13L is currently considered to be a single-
gene cause of complex cyanotic heart defects. Two patients with
non-syndromic intellectual disability (ID) and homozygous MED13L
gene variants have been recently reported.11 Despite the knowledge
that common molecular mechanisms can cause congenital heart
defects and neurodevelopmental diseases, complications of a con-
genital heart defect and possible surgical procedures have been held
responsible for later apparent developmental delay in many cases.
Here, we report a cohort of eight patients with mutant MED13L who
lack complex congenital heart malformations but display facial
dysmorphism, ID, speech impairment, motor developmental delay
with muscular hypotonia and behavioral difﬁculties. This strongly
supports a broader clinical spectrum of the MED13L syndrome than
previously acknowledged.
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PATIENTS AND METHODS
Patients
Local ethics committees approved genetic studies, and their parents provided
written informed consent for the molecular genetic analysis and the publication
of clinical and radiological data as well as photographs. Mutations and
phenotypic details were submitted to DECIPHER (https://decipher.sanger.ac.uk/).12
Genetic studies: molecular karyotyping and whole-exome
sequencing
Genomic DNA and RNA samples were extracted from peripheral blood and
lymphoblastoid cell lines according to standard protocols, respectively. For
index 1, CGH microarray analysis was performed using the Agilent 244 K
microarray chip. Parental DNA was assessed for the presence of the same
microduplication using multiplex ligation-dependent probe ampliﬁcation.
Proband genomic DNA was sequenced for variants in PTPN11, SOS1, RAF1,
KRAS, BRAF, MAP2K1, HRAS, MAP2K2, SHOC2, NRAS, CBL and SPRED1.
No variants predicted to be deleterious were discovered (data not shown). For
indexes 2, 3 and 5, copy number proﬁling was performed on 180 K
oligonucleotide arrays (Agilent Technologies Inc., Diegem, Belgium) according
to the manufacturer's instructions or with minor modiﬁcations as described.13
Copy number variation was evaluated using the in-house developed software
tool arrayCGHbase.14 For indexes 4 and 8, CGH microarray analysis was
performed on a human genome CGH Agilent 180 K custom array designed by
the Low Lands Consortium (Dr Klas Kok) for the analysis of children with ID/
developmental delay (AMADID:023363; Agilent Technologies Inc., Santa Clara,
CA, USA). DNA labeling was performed using the ENZO Labeling Kit for
Oligo Arrays (Enzo Life Sciences, Inc., Farmingdale, NY, USA) and MegaPoll
reference DNA from Kreatech Diagnostics (Amsterdam, The Netherlands).
Arrays were hybridized using the Agilent SurePint G3 Human CGH Microarray
Kit, and data were extracted with the Agilent Feature Extraction (FE) Software
v10.5 using default settings for CGH hybridizations. Image analysis was
performed using the across-array methodology described previously.15 CGH
data were analyzed using Nexus Copy Number 5.0 software (BioDiscovery,
Hawthorne, CA, USA) with FASST Segmentation algorithm. For index 6 and
her parents, genomic DNA was enriched using the Agilent SureSelect and
whole-exome sequencing was performed, followed by bioinformatic
analysis.11,16 The variant in MED13L was conﬁrmed by PCR and Sanger
sequencing. For index 7, Baylor BAC array CGH Version V6 and Agilent 105 K
oligonucleotide array were performed. Interphase FISH (clone RP11-902D13)
further conﬁrmed a one-copy gain (data not shown). MED13L exons are
numbered according to NG_023366.1.
Reverse transcription PCR (RT-PCR)
RT-PCR on index 2 and control cDNA was performed with MED13L primer
set 5′-CGCGGAGGATCATGACTG-3' and 5′-TCCCAACTCGTCTTCCTCTT-3'.
Speciﬁc PCR products were Sanger sequenced using the same primer set.
Quantitative PCR analysis
Primers for qPCR were designed for MED13L (ENSG00000123066) and the
reference genes SDC4 (ENSG00000124145) and ZNF80 (ENSG00000174255).
Primers and PCR conditions are available from the authors on request.
Quantiﬁcation was performed as described elsewhere.17
RESULTS
Patients with MED13L variants present with syndromic ID
By applying array CGH and whole-exome sequencing, we identiﬁed
novel heterozygous MED13L variants, including microdeletions,
microduplications and a de novo exonic dinucleotide deletion
(Supplementary Figures 1 and 2A). These patients presented with
strikingly consistent facial dysmorphism, variable degree of ID, speech
impairment, motor developmental delay with muscular hypotonia,
motor coordination difﬁculties, ataxia and behavioral difﬁculties.
Remarkably, none of the patients had complex congenital heart
defects (Table 1, Figure 1).
Index patient 1 was born at 37 weeks as the only affected child of a
dizygotic twin pair of healthy, non-consanguineous American Caucasian
parents (DECIPHER no. 296364). Her birth length was 48 cm (10−25
centile, −0.9 SD), weight was 2810 g (10−25 centile, −0.9 SD) and occipito-
frontal head circumference (OFC) was 33 cm (10 centile, −1.2 SD), all
normal. She presented with facial dysmorphism including a triangular
face with low set ears and a bulbous nose, upslanted palpebral ﬁssures,
hypertelorism, ptosis, widely spaced teeth and prognathism, as well as
a short neck. Clinical evaluation further revealed a high arched
palate, bilateral cubitus valgus, adduction of feet, muscular hypo-
tonia, poor coordination without ataxia and normal deep tendon
reﬂexes. Language and motor development were severely delayed
(ﬁrst words spoken after 15 months, unaided walking after 3 years),
and mild-to-moderate ID was present. Testing at 6 years with the
Peabody Picture Vocabulary Test revealed a standard score of 70 (2
centile), equivalent to that expected at a chronological age of 3.5
years. On the CELF-Preschool test, she demonstrated sentence
structure and expressive vocabulary skills signiﬁcantly below her
age with challenges particularly in speech intelligibility and verbal
comprehension, but with strengths in her social communications
skills. At 5.5 years, her Peabody Developmental Motor Scale
revealed a Fine Motor Quotient of 73 (12 centile), and her Beery
Test of Visual Motor Integration score was 66 (1 centile). She is
myopic. Chronic ear infections in early childhood ceased after
insertion of typanostomy tubes at age 2. Echocardiography revealed
a structurally normal heart. She displays normal, non-autistic behavior.
Her current height at 11 years is 143 cm (25− 50 centile, − 0.5 SD),
weight 46 kg (75− 90 centile, 0.8 SD), and OFC 55.5 cm (90− 97
centile, +2 SD). Array CGH analysis identiﬁed a de novo heterozygous
likely intragenic duplication of MED13L exons 2–4 (180 kb, chr12.
hg19:g.(116,484,299_116,497,981)_(116,681,549_116,695,774)dup)
predicted to disrupt the gene.
Index patient 2 was born at term as the fourth child of healthy,
non-consanguineous Caucasian parents of Belgium descent following
a pregnancy complicated by gestational diabetes (DECIPHER no.
257915). Birth weight (3050 g; 10− 25 centile, − 0.7 SD), length
(49 cm; 10− 25 centile, − 0.8 SD) and OFC (35 cm; 25− 50 centile,
–0.3 SD) were normal. He had a broad forehead, mild bitemporal
narrowing, epicanthal folds, ﬂat and broad nasal bridge, rounded nasal
tip, broad columella, low set, posteriorly rotated ears with an uplift of
the ear lobule, marked philtrum and full lips. He showed ﬁfth ﬁnger
clinodactyly. Language and motor development were severely delayed
(ﬁrst words spoken at 3 years, unaided sitting and walking at 13 and
24 months, respectively). Cognitive development was delayed by
8 months at the age of 22 months (Bayley’s Scale of Infant
Development) and by 20 months at the age of 40 months (Bayley’s
scale II of infant development: developmental indexo55). Clinical
evaluation revealed muscular hypotonia including poor feeding as an
infant and facial hypotonia with drooling. In addition, he displayed
unilateral cryptorchidism, hyperreﬂexia without spasticity or pyramidal
signs, ataxia, and autistic behaviors (stereotypic movements, avoidance
of eye contact). Weight (12.5 kg, 10 centile), height (93 cm, 10 centile)
and OFC (49.5 cm, 25 centile) were normal at the age of 3 years. He
suffered from recurrent upper respiratory tract infections during
childhood treated with prophylactic inhalation steroids. Cranial
magnetic resonance imaging (cMRI) revealed delayed (cortical)
myelination. No heart defect was identiﬁed through echocardiogram.
Array CGH followed by RT-PCR of patient derived RNA
(Supplementary Figure 2B and data not shown) identiﬁed a de novo
heterozygous deletion of MED13L exons 3–4 (125 kb, chr12.hg19:g.
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(116,440,087_116,466,743)_(116,591,383_116,616,387)del) predicted
to produce a frameshift leading to a truncated protein.
Index patient 3 was born at term as the ﬁrst child of healthy, non-
consanguineous Caucasian parents of French descent (DECIPHER no.
255109) with congenital torticollis and preauricular tags. Birth weight,
length and OFC were 2590 g (5− 10 centile, − 1.4 SD), 47.5 cm
(10− 25 centile; − 1.1 SD) and 33 cm (10 centile, − 1.1 SD). Facial
dysmorphism at 20 months included plagiocephaly, brachycephaly,
frontal bossing, frontal hair upsweep, large anterior fontanel, facial
asymmetry with macrostomia, upslanting small palpebral ﬁssures and
strabismus. She had a short neck, was severely hyperopic and had
astigmatism. Global psychomotor delay was present with a severe
speech delay and moderate ID. She did not speak any word at 4 years
but understood simple orders, sat at 10 months and walked at 3 years.
Her anthropometric data at that time were: weight 14.6 kg (25− 50
centile, − 0.5 SD), length 96 cm (10− 25 centile, − 0.9 SD) and OFC
51 cm (75 centile, +1 SD). No autistic behavior could be detected.
A short and thick corpus callosum, a cyst from cavum vergae and an
arachnoid cyst were evident on cMRI. Cardiac and abdominal
ultrasounds revealed normal results. Array CGH analysis revealed a
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Figure 1 Phenotype and genotype of patients with MED13L gene mutations. (a) Pictures of index patients 1–9 illustrating the typical facial features
including a broad forehead, bitemporal narrowing, low set ears, upslanted palpebral ﬁssures, ﬂat nasal root, broad nasal tip, macrostomia with an open-
mouth appearance and frontal bossing. (b) Skeletal features include ﬁfth ﬁnger clinodactyly (index patient 2), arthrogryposis and ulnar deviated club hands,
as well as camptodactyly of the toes and cutaneous syndactyly of toes 2–3 (index patient 5), clinodactyly of the ﬁfth rays of both hands (index patient 6) and
short thumbs (index patient 7). (c) Diagrammatic presentation of the MED13L gene with exons 1–31 (intronic regions are not drawn to scale). The mutations
identiﬁed in the index patients reported here are highlighted in bold print, and previously published mutations are indicated in normal print.
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heterozygous likely intragenic duplication of MED13L exons 5–28
(60 kb, chr12.hg19:g.(116,403,831_116,405,600)_(116,469,708_116,470,
897)dup), predicted to disrupt the gene. Quantitative PCR conﬁrmed
the duplication and showed that it was de novo.
Index patient 4 was born at 35 weeks of gestation, by cesarean
section due to preeclampsia, as the only child of non-consanguineous
parents of Portuguese descent (DECIPHER no. 272268). His mother,
who received carbamazepine for epilepsy, had ceased her anticonvulsant
therapy starting 3 months preconception. Birth weight (2330 g; 25
centile), length (47 cm; 25–50 centile) and OFC (33 cm; 75 centile) were
normal. Facial dysmorphism included frontal hair upsweep, upslanting
palpebral ﬁssures, thick eyebrows with medial ﬂare, wide and depressed
nasal bridge, broad nasal tip, low set ears, frontal bossing, wide and
often open mouth with downturned corners, and bulbous macrostomia
with thick lip vermilion. Arthrogryposis of the hands, ulnar deviated
club hands, camptodactyly of the toes, cutaneous syndactyly of toes 2–3
and decreased palmar creases were noted. In the neonatal period, he
developed hyaline membrane disease, and congenital pneumonia was
diagnosed, requiring 3 weeks at the neonatal intensive care unit. Other
transitory problems at this time were neonatal jaundice and one seizure.
Results of cranial ultrasound were normal. Recurrent mostly respiratory
infections (including another episode of pneumonia at the age of 4
years) improved signiﬁcantly after the age of 6 years. At the age of 15
years, he still has wheezing episodes, requiring prophylactic medication
with the H1-antihistamine and mast cell stabilizer ketotifen. Global
developmental delay was noticed early on. He had severe speech delay
or poor speech (only few words spoken at 15 years), moderate ID (IQ
43; Ruth Grifﬁths developmental scale) and motor delay with muscular
hypotonia (unaided sitting and walking at 12 and 20 months, respec-
tively). Clinical examination further revealed an uncoordinated gait,
agitation, restlessness, overfriendliness and hyperactivity with a Vineland
Adaptive Behavior Scale (VABS) score of 27 indicating severely deﬁcient
adaptive behavior and a Conner’s questionnaire revealing a hyperkinesia
score of 21. Growth parameters were normal at the age of 15 years (50
centile for weight/stature and 10 centile for OFC). His visual and
auditory function is normal, and results of abdominal ultrasound and
cMRI were normal. Neurological examination was otherwise normal.
Array CGH revealed a de novo 0.3Mb likely intragenic duplication
of MED13L exons 2–26 (chr12.hg19:g.(116,420,188_116,397,305)_
(116,695,775_116,712,831)dup), predicted to disrupt the gene.
Index patient 5 was born at term as the ﬁrst child of non-
consanguineous healthy parents of Belgian descent after an uneventful
pregnancy induced by ICSI. Her birth weight (3250 g, 25− 50 centile,
− 0.1 SD), length (50 cm, 25− 50 centile, − 0.2 SD) and OFC (35 cm,
50 centile, 0 SD) were normal. Motor development was delayed with
unaided sitting and walking at 10 and 21 months, respectively. Speech
delay was observed (ﬁrst words spoken at 24 months and further
impaired expression). Clinical examination at the age of 35 months
revealed facial dysmorphism with a broad forehead, slight bitemporal
narrowing, epicanthal folds, broad nasal bridge, rounded nasal tip,
marked philtrum, full lips and slight uplift of the ear lobules. A
proportionate and congruent short stature developed during the ﬁrst
year of life, but, thereafter, anthropometric values followed the
respective centile curves. At the age of 3 years, her height was 88 cm
(3− 10 centile, − 1.3 SD), weight 12.4 kg (below 3 centile, − 2.6 SD)
and OFC 48 cm, (25− 50 centile, − 0.3 SD). Her global development
was delayed by 1 year (Bayley’s II Scale of Infant Development score
o55), and muscular hypotonia, intoeing, hypermetropia (+4 dtp),
strabismus and bilateral clinodactyly of the ﬁfth rays of her hands was
present. She also showed aggressive behavior but had otherwise
normal results on neurological examination. She suffered from
recurrent upper airway infections and one episode of pyelonephritis.
Three small liver cysts were revealed by abdominal ultrasound,
whereas echocardiography results were normal. cMRI revealed peri-
ventricular small round signal alterations of the white matter in line
with a myelination disorder (data not shown). Array CGH identiﬁed a
de novo deletion of MED13L exons 2–22 (276 kb, chr12.hg19:g.
(116,392,761_116,420,188)_(116,695,775_116,712,831)del), predicted
to result in a smaller protein of 509 amino acids.
Index patient 6 was born at term without complications as the
second of two children of healthy, non-consanguineous parents of
German descent (DECIPHER no. 295729). She had facial dysmorphism
(hypertelorism, ﬂat midface), a simian crease, short thumbs and an
umbilical hernia. A global developmental delay was present with
delayed motor milestones (unaided sitting and walking at 15 and
24 months, respectively), ID (IQ of Snijders-Oomen non-verbal
intelligence test subcategories 58–85), speech delay or poor speech
(50 words at the age of 6 years, communication with single words
only) and autistic behavior. A discrete bilateral high-tone hearing loss
was present, but her hearing threshold level was normal. Anthropo-
metric data were normal at 6 years (height 109 cm, 5− 10 centile, − 3.2
SD; weight 18 kg, 10− 25 centile, − 0.9 SD; OFC 51 cm, 25− 50
centile, − 0.2 SD). Echocardiogram revealed no signiﬁcant abnormality
except for small patent foramen ovale (PFO). EEG disclosed
irregular multifocal spike and wave complexes. Results of cMRI,
abdominal ultrasound and ophthalmological exam were normal.
Whole-exome sequencing revealed a de novo heterozygous 2-bp
deletion in MED13L exon 27 (chr12:116,408,516_116 ,408,517delGA)
leading to a frameshift and premature stop codon (p.(Gln1984A-
lafs*31)) in the patient.
Index patient 7 is the 8-year-old son of non-consanguineous
parents of Scottish, Irish and Ashkenazi Jewish American descent
(DECIPHER no. 296365). Facial dysmorphism include triangular
facies, short philtrum, prominent columella, low set ears with irregular
antihelices and widely spaced teeth. The patient had delayed motor
development, a speech delay, and a learning disability, but no ID.
Further, tics, unilateral conductive hearing loss, pectus excavatum and
small but fully descended testes were noted. Echocardiogram revealed
a small PFO with left-to-right shunt. Anthropometric values were
normal (height 127 cm, 10− 25 centile; weight 25 kg, 25 centile; OFC
54 cm, 75 centile). Two other family members, the index’s mother and
a female sibling, had the same facial appearance (Supplementary
Figure 3), but with delayed menarche only and no other signiﬁcant
medical issues. Array CGH revealed an approximately 3-Mb micro-
duplication that includes MED13L as well as 11 other genes co-
segregating with facial dysmorphism in the family (chr12.hg19:g.
(114,948,852_115 ,057,027)_(118,248,051_118,272,276)dup).
Index patient 8 was born at term, by ventouse delivery, as the only
child of non-consanguineous, healthy parents of Portuguese descent
(DECIPHER no. 272267). During pregnancy increased nuchal trans-
lucency and a single umbilical artery were detected. Somatometric
parameters were normal: weight 3269 g (50 centile, − 0.04 SD), length
49.5 cm (25− 50 centile, − 0.4 SD), OFC 33 cm (10 centile, − 1.1 SD).
Motor development was delayed (unaided sitting and walking at 12
and 36 months, respectively), and ID was moderate with an IQ of 49.
She had an expressive language delay with 5–6 words spoken at the age
of 4 years. Clinical examination revealed facial dysmorphism
characterized by a round face, brachycephaly, bitemporal narrowing,
deeply set eyes, horizontal and laterally extended eyebrows, lower lid
entropion, depressed nasal bridge, low set and posteriorly rotated ears,
and an open mouth with downturned corners. Further anomalies
present included inverted and hypoplastic nipples and an anteriorly
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placed anus. Results of neurological examination were otherwise
normal. A small perimembranous ventricular septum defect without
hemodynamic repercussion, revealed by echocardiography at the age
of 2 months, had closed spontaneously at 3 years. Anthropometric
values were normal (50 centile for height, weight and OFC). cMRI
results were normal. Array CGH revealed a de novo 1.9-Mb deletion
that includes MED13L as well as seven other genes (chr12.hg19:g.
(115,513,181_115, 497, 819)_(117,432,905_117, 450,462)del).
DISCUSSION
In this study, we report seven patients with protein truncating variants
caused byMED13L exon deletions or duplications (indexes 1–6 and 8)
and a family with a large duplication including MED13L (index 7,
discussed below) (Table 1, Figure 1). All individuals with MED13L
truncating variants have ID and display common characteristic facial
features characterized by a broad prominent forehead, bitemporal
narrowing, low set ears, upslanted palpebral ﬁssures, ﬂat nasal root,
broad nasal tip and macrostomia with an open-mouth appearance.
Further common clinical features are delayed speech and language
development typically with near-totally absent speech, motor developmental
delay with muscular hypotonia as well as coordination problems
(often with ataxia), and behavioral difﬁculties. Individual patients
developed postnatal short stature. None of the patients had a complex
congenital heart defect.
These results argue strongly against the previous notion that
MED13L haploinsufﬁciency is a single-gene cause for complex
congenital heart defects only (for an overview of previously reported
MED13L patients see Table 2). Indeed, the extent to which the cardiac
phenotype is a feature of the MED13L syndrome is unclear. In the
initial study on 97 patients with complex congenital heart disease
(d-TGA), MED13L missense variants and a gene interruption were
identiﬁed in four patients. However, one of the missense changes was
also present in the healthy mother, for the remaining two additional
evidence for pathogenicity was not provided, and the patient with
MED13L interruption did not have ‘isolated’ d-TGA as suggested in
the abstract of the paper, but rather a syndromic form reminiscent of
that in our patients.3 Moreover, in a study of 102 patients with d-TGA,
no variant in the MED13L gene could be identiﬁed arguing at least
against a high incidence of MED13L-associated heart disease.18 Recent
reports of individuals with MED13L variants who lacked a cardiac
phenotype provided some evidence to argue against the MED13L-
heart phenotype hypothesis.19–23 Similarly, a study on 343 patients
with autism spectrum disorder, reported one potential splice-site
change in an affected individual.24 Unfortunately, clinical information
on this patient is not available. In view of our study, these results
merge nicely into the extended spectrum of the MED13L syndrome
that we propose with both the cardiac phenotype and autism being
possible but not required features for diagnosis.
The MED13L phenotype appears to underlie a gradient. Although
some patients suffer from a severe phenotype with dysmorphism, global
developmental delay and complex congenital heart disease, other
patients with MED13L variants do not display a recognizable cardiac
phenotype. This also applies to individuals with apparently identical
exon deletions. For example, de novo deletions of MED13L exons 3 and
4 are associated with the typical facial features of MED13L syndrome in
two individuals that are, however, discordant with respect to the cardiac
phenotype (index patient 2 in this study and patient 2 reported in
Asadollahi et al4). Here, the genetic background or stochastic factors
may have a role in the penetrance of the cardiac phenotype. Going
further, the cardiac phenotype may be the least susceptible to MED13L
perturbation and the least useful marker of the condition because both
individuals are otherwise phenotypically identical. Although two patients
with non-syndromic ID carried a homozygous MED13L missense
variant, no record of a phenotype in the respective parents, who are
Table 3 Key phenotype features of mediator complex-associated diseases
Domains MED12 (Opitz–Kaveggia) MED12 (Lujan–Fryns) MED13L
Cognitive Intellectual disability, usually severe Intellectual disability Intellectual disability
Head Macrocephaly (relative) Macrocephaly (enlarged skull) with a
prominent forehead
Brachycephaly, frontal bossing
Upswept frontal hairline Frontal hair upsweep or low anterior
hairline
Ears Small, underdeveloped ears Low set ears with some apparent
retroversion
Low set ears
Eyes Down-slanting palpebral ﬁssures Upslanting palpebral ﬁssures
Widely set eyes (hypertelorism), Mild hypertelorism
Muscle Severe hypotonia; Hypotonia Hypotonia
A characteristic facial appearance due to hypotonia,
giving a droopy, 'open-mouthed' expression
Facial hypotonia with droopy open-
mouthed expression
A thin upper lip, a full or pouting lower lip
Brain Partial or complete loss of the corpus callosum Partial or complete loss of the corpus
callosum
Cardiac Heart defects Dilation of the aortic root, ventricular
and atrial septal defect
Some cases with d-TGA, other
complex cardiac defects
Genitalia Cryptorchidism (males) Slightly enlarged to normal testicular
size in males
Cryptorchidism or micropenis
Chest Pectus excavatum
Miscellaneous features unique
to each syndrome
Hyperactive behavior; severe constipation, with or without
structural anomalies in the anus such as imperforate anus,
broad thumbs and wide ﬁrst (big) toes
Maxillary hypoplasia, seizures,
Marfanoid habitus
Autistic and/or hyperactive behavior
(not always present)
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heterozygous carriers for the same variant, is noted.11 Increased
MED13L dosage appears not to confer the same degree of disease
risk as haploinsufﬁciency. The phenotype was surprisingly mild in
index patient 7, his mother and sister with duplication of chromo-
some 12q24.2.q24.23 and in a previously reported patient with a
triplication of chromosome 12, both involving the MED13L gene
and several other genes.4 Although in these cases, the individual
effect of increased MED13L dosage cannot be determined because
of the involvement of several genes, it further underlines a possible
gene dosage effect.
MED13L is only one component of the mediator complex linked to
human disease: (i) MED12 gene variants cause Lujan-Fryns syndrome
(MIM #309520),25 Ohdo syndrome (MIM #300895),26 Opitz-Kaveggia
syndrome (MIM #305450),27 and profound ID that in contrast to the
aforementioned syndromes resulted in affected female carriers and
truncation of the MED12 protein,28 (ii) a recurrent homozygous
MED17 missense variant has been linked to postnatal progressive
microcephaly with seizures and brain atrophy (MIM #613668),29
(iii) a homozygous MED23 variant causes autosomal recessive non-
syndromic ID (MIM #614249),30 (iv) a homozygous MED25 variant
causes autosomal recessive adult onset axonal Charcot-Marie-Tooth
neuropathy (CMT2B2, MIM #605589)31 and (v) a truncation of
CDK19 caused by a chromosome inversion is associated with bilateral
congenital retinal folds, microcephaly, and mild ID (MIM #614720).32
We observe that theMED13L phenotype displays similarities to Opitz-
Kaveggia syndrome, along with key differences (see Table 3). Indeed,
MED12 and MED13/MED13L are closely associated with the CDK8
module, which has a distinct role in regulating mediator function and
transcription.5,33 Mammalian mediator exists primarily in two forms
distinguished by the presence or absence of the CDK8 module, the latter
containing the four subunits CDK8, CCNC, MED12 and MED13.
MED13 physically links the CDK8 module to the mediator core, and it is
suspected that the less-characterized MED13L has similar functions.9
Although mediator proteins in general are associated with diverse
functions and, when dysfunctional, with various disease pheno-
types, we hypothesize that components that show some degree of
functional overlap may be more likely to share phenotypic features
with each other.
In conclusion, deleterious MED13L variants cause a recognizable
dysmorphic syndrome, but contradictory to what is presented in the
majority of the literature cardiac disease is not an invariable feature of
the phenotype. We suggest that there is a MED13L phenotypic
gradient given the observations of a variable phenotype from severe
dysmorphism with global developmental delay to non-syndromic ID.
There is phenotype overlap between MED13L syndrome and MED12
syndromes, and it is likely that variants in further complex compo-
nents will be identiﬁed with similar phenotypes. Beyond the emerging
recognition of a MED13L syndrome, our ﬁndings also underline
common molecular factors associated with neurodevelopmental
diseases and congenital heart defects.
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